$DGX
Quest Diagnostics Inc

2024 Q3 Form 10-Q Financial Statement

#000102207924000156 Filed on July 24, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $2.397B
YoY Change 2.52%
Cost Of Revenue $1.593B
YoY Change 3.04%
Gross Profit $804.0M
YoY Change 1.52%
Gross Profit Margin 33.54%
Selling, General & Admin $416.0M
YoY Change 1.71%
% of Gross Profit 51.74%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $117.0M
YoY Change 4.46%
% of Gross Profit 14.55%
Operating Expenses $416.0M
YoY Change -4.81%
Operating Profit $355.0M
YoY Change 0.0%
Interest Expense $47.00M
YoY Change -227.03%
% of Operating Profit 13.24%
Other Income/Expense, Net -$41.00M
YoY Change -783.33%
Pretax Income $314.0M
YoY Change -0.95%
Income Tax $74.00M
% Of Pretax Income 23.57%
Net Earnings $229.0M
YoY Change -2.14%
Net Earnings / Revenue 9.55%
Basic Earnings Per Share $2.05
Diluted Earnings Per Share $2.03
COMMON SHARES
Basic Shares Outstanding 111.3M shares 111.1M shares
Diluted Shares Outstanding 112.0M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.0M
YoY Change 115.08%
Cash & Equivalents $271.0M
Short-Term Investments
Other Short-Term Assets $245.0M
YoY Change 30.32%
Inventory $182.0M
Prepaid Expenses
Receivables $1.319B
Other Receivables $0.00
Total Short-Term Assets $2.017B
YoY Change 16.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.832B
YoY Change -24.45%
Goodwill $7.885B
YoY Change 1.97%
Intangibles $1.202B
YoY Change -3.61%
Long-Term Investments $126.0M
YoY Change -6.67%
Other Assets $216.0M
YoY Change 42.11%
Total Long-Term Assets $11.86B
YoY Change 1.47%
TOTAL ASSETS
Total Short-Term Assets $2.017B
Total Long-Term Assets $11.86B
Total Assets $13.88B
YoY Change 3.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.247B
YoY Change 3.83%
Accrued Expenses $159.0M
YoY Change 1.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $606.0M
YoY Change 16.99%
Total Short-Term Liabilities $2.012B
YoY Change 7.31%
LONG-TERM LIABILITIES
Long-Term Debt $3.816B
YoY Change 1.03%
Other Long-Term Liabilities $811.0M
YoY Change -42.44%
Total Long-Term Liabilities $811.0M
YoY Change -84.36%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.012B
Total Long-Term Liabilities $811.0M
Total Liabilities $2.823B
YoY Change -60.66%
SHAREHOLDERS EQUITY
Retained Earnings $9.080B
YoY Change 6.0%
Common Stock $2.316B
YoY Change 1.31%
Preferred Stock
YoY Change
Treasury Stock (at cost) $4.760B
YoY Change 3.77%
Treasury Stock Shares
Shareholders Equity $6.617B
YoY Change
Total Liabilities & Shareholders Equity $13.88B
YoY Change 3.4%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income $229.0M
YoY Change -2.14%
Depreciation, Depletion And Amortization $117.0M
YoY Change 4.46%
Cash From Operating Activities $360.0M
YoY Change -18.92%
INVESTING ACTIVITIES
Capital Expenditures $92.00M
YoY Change -11.54%
Acquisitions $106.0M
YoY Change -81.66%
Other Investing Activities -$108.0M
YoY Change -81.31%
Cash From Investing Activities -$200.0M
YoY Change -70.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -363.0M
YoY Change -292.06%
NET CHANGE
Cash From Operating Activities 360.0M
Cash From Investing Activities -200.0M
Cash From Financing Activities -363.0M
Net Change In Cash -203.0M
YoY Change 314.29%
FREE CASH FLOW
Cash From Operating Activities $360.0M
Capital Expenditures $92.00M
Free Cash Flow $268.0M
YoY Change -21.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Central Index Key
EntityCentralIndexKey
0001022079
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
Quest Diagnostics Inc
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
16-1387862
dei Entity Address Address Line1
EntityAddressAddressLine1
500 Plaza Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Secaucus,
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07094
dei City Area Code
CityAreaCode
(973)
dei Local Phone Number
LocalPhoneNumber
520-2700
dei Security12b Title
Security12bTitle
Common Stock, $0.01 Par Value
dei Trading Symbol
TradingSymbol
DGX
dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
1546000000 usd
us-gaap Cost Of Revenue
CostOfRevenue
3188000000 usd
us-gaap Cost Of Revenue
CostOfRevenue
3106000000 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
416000000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
416000000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
856000000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
855000000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29000000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
28000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54000000 usd
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-4000000 usd
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-6000000 usd
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-1000000 usd
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
2042000000 usd
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
1990000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
4108000000 usd
us-gaap Costs And Expenses
CostsAndExpenses
4016000000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
355000000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
348000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
655000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
653000000 usd
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-44000000 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-37000000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-87000000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-72000000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
13000000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41000000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-75000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59000000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
314000000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
317000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
580000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
594000000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74000000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
140000000 usd
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114000000 shares
CY2024Q2 us-gaap Profit Loss
ProfitLoss
240000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
249000000 usd
us-gaap Profit Loss
ProfitLoss
448000000 usd
us-gaap Profit Loss
ProfitLoss
466000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
237000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
251000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
443000000 usd
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
471000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
11000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
14000000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
25000000 usd
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
29000000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
226000000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
237000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
418000000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
442000000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
686000000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
27000000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1319000000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1210000000 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
182000000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
603000000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
602000000 usd
CY2024Q2 us-gaap Goodwill
Goodwill
7885000000 usd
CY2023Q4 us-gaap Goodwill
Goodwill
7733000000 usd
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1202000000 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1166000000 usd
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
126000000 usd
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
135000000 usd
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
216000000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
198000000 usd
CY2024Q2 us-gaap Assets
Assets
13881000000 usd
CY2023Q4 us-gaap Assets
Assets
14022000000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1247000000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1359000000 usd
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
606000000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
303000000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
159000000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
153000000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2012000000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1815000000 usd
CY2024Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
3816000000 usd
CY2023Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
4410000000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
507000000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
503000000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
162000000 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
2000000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
2000000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2314000000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2320000000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
9080000000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
6307000000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
39000000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
35000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6656000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6342000000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13881000000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14022000000 usd
us-gaap Profit Loss
ProfitLoss
448000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
219000000 usd
us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
3000000 usd
us-gaap Contract With Customer Asset Credit Loss Expense
ContractWithCustomerAssetCreditLossExpense
-1000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-36000000 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-16000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
42000000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
40000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-16000000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-1000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
113000000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
38000000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-111000000 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-156000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
20000000 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
5000000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-12000000 usd
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-18000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
514000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
538000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
248000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
609000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
196000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
231000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-31000000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-413000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-840000000 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
1147000000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
301000000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
828000000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
271000000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
126000000 usd
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Amendment Flag
AmendmentFlag
false
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
111317208 shares
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2397000000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2338000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4763000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4669000000 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
1593000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
140000000 usd
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7000000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8000000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
12000000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
240000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
249000000 usd
us-gaap Profit Loss
ProfitLoss
448000000 usd
us-gaap Profit Loss
ProfitLoss
466000000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
25000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
29000000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
229000000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
235000000 usd
us-gaap Net Income Loss
NetIncomeLoss
423000000 usd
us-gaap Net Income Loss
NetIncomeLoss
437000000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.88
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.83
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112000000 shares
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
271000000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
27000000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
190000000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
245000000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
286000000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
2017000000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
2372000000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1832000000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1816000000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
811000000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
876000000 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
76000000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
8825000000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19000000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-14000000 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
51000000 shares
CY2024Q2 us-gaap Treasury Stock Value
TreasuryStockValue
4760000000 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
4826000000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
6617000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
233000000 usd
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111000000 shares
CY2024Q2 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
79000000 usd
CY2024Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
51000000 shares
us-gaap Profit Loss
ProfitLoss
466000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
47000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
23000000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
28000000 usd
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
163000000 usd
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
154000000 usd
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
18000000 usd
us-gaap Payments Of Dividends Minority Interest
PaymentsOfDividendsMinorityInterest
28000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-39000000 usd
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-43000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-516000000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-415000000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-189000000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
686000000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
315000000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6469000000 usd
CY2024Q2 dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
238000000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000000 usd
CY2024Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
84000000 usd
CY2024Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
7000000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
7000000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
20000000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6656000000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6342000000 usd
dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
445000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5000000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
168000000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
18000000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
23000000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6656000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6088000000 usd
CY2023Q2 dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
247000000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2000000 usd
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
81000000 usd
CY2023Q2 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
12000000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
9000000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16000000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6287000000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
5930000000 usd
dgx Net Income Loss Excluding Redeemable Noncontrolling Interest
NetIncomeLossExcludingRedeemableNoncontrollingInterest
463000000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
5000000 usd
us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
161000000 usd
us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
25000000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
15000000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40000000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000000 usd
us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
28000000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
6287000000 usd
us-gaap Nature Of Operations
NatureOfOperations
DESCRIPTION OF BUSINESS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Background</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">    </span></div>    Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") work across the healthcare ecosystem to create a healthier world, one life at a time. The Company's diagnostic information services ("DIS") business provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, the diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, the diagnostic insights can inspire actions that transform lives and create a healthier world. The Company provides services to a broad range of customers within its primary customer channels - physicians (including those associated with accountable care organizations and Federally Qualified Health Centers), hospitals, and patients and consumers. Other customers include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories. The Company offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company's large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding the Company's tests and test results, and help them best utilize Quest Diagnostics' services to improve outcomes and enhance satisfaction. The Company's Diagnostic Solutions ("DS") group, which represents the balance of the Company's consolidated net revenues, includes the Company's risk assessment services business, which offers solutions for insurers, and the Company's healthcare information technology businesses, which offer solutions for healthcare providers and payers.
us-gaap Use Of Estimates
UseOfEstimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
229000000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
235000000 usd
us-gaap Net Income Loss
NetIncomeLoss
423000000 usd
us-gaap Net Income Loss
NetIncomeLoss
437000000 usd
CY2024Q2 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000 usd
CY2023Q2 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
1000000 usd
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
2000000 usd
us-gaap Participating Securities Distributed And Undistributed Earnings Loss Diluted
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossDiluted
2000000 usd
CY2024Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
228000000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
234000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
421000000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
435000000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
111000000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112000000 shares
CY2024Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000000 shares
CY2023Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1000000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2000000 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112000000 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112000000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114000000 shares
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.05
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.79
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.88
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.03
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.83
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1000000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2024Q2 us-gaap Restructuring Charges
RestructuringCharges
8000000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
1000000 usd
us-gaap Restructuring Charges
RestructuringCharges
14000000 usd
us-gaap Restructuring Charges
RestructuringCharges
16000000 usd
CY2024Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Asset Impairment Charges
AssetImpairmentCharges
5000000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
5000000 usd
CY2024Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
8000000 usd
CY2023Q2 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
6000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
14000000 usd
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
21000000 usd
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
248000000 usd
us-gaap Payment For Contingent Consideration Liability Investing Activities
PaymentForContingentConsiderationLiabilityInvestingActivities
6000000 usd
CY2023Q4 dgx Prepayments To Acquire Businesses Net Of Cash Acquired
PrepaymentsToAcquireBusinessesNetOfCashAcquired
30000000 usd
dgx Prepayments To Acquire Businesses Net Of Cash Acquired
PrepaymentsToAcquireBusinessesNetOfCashAcquired
30000000 usd
CY2024Q2 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
154000000 usd
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
154000000 usd
CY2024Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4300000000 usd
CY2023Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
4600000000 usd
CY2024Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.75
CY2024Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.75
CY2023Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2023Q4 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2023Q3 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.71
CY2024Q2 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
1000000000 usd
us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
700000 shares
us-gaap Stock Issued During Period Shares Treasury Stock Reissued
StockIssuedDuringPeriodSharesTreasuryStockReissued
900000 shares
CY2024Q2 us-gaap Depreciation
Depreciation
88000000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
84000000 usd
us-gaap Depreciation
Depreciation
175000000 usd
us-gaap Depreciation
Depreciation
165000000 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29000000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
28000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
54000000 usd
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
117000000 usd
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
112000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
233000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
219000000 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
47000000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
39000000 usd
us-gaap Interest Expense
InterestExpense
96000000 usd
us-gaap Interest Expense
InterestExpense
76000000 usd
CY2024Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
3000000 usd
CY2023Q2 us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
2000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
9000000 usd
us-gaap Interest And Dividend Income Operating
InterestAndDividendIncomeOperating
4000000 usd
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-44000000 usd
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-37000000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-87000000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-72000000 usd
CY2024Q2 us-gaap Interest Paid Net
InterestPaidNet
61000000 usd
CY2023Q2 us-gaap Interest Paid Net
InterestPaidNet
48000000 usd
us-gaap Interest Paid Net
InterestPaidNet
105000000 usd
us-gaap Interest Paid Net
InterestPaidNet
80000000 usd
CY2024Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
115000000 usd
CY2023Q2 us-gaap Income Taxes Paid
IncomeTaxesPaid
101000000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
118000000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
134000000 usd
CY2024Q2 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000000 usd
CY2023Q2 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
31000000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
29000000 usd
CY2024Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
84000000 usd
CY2023Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
81000000 usd
CY2024Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
84000000 usd
CY2023Q2 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
81000000 usd
CY2024Q2 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
134000000 usd
CY2023Q2 us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
703000000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
289000000 usd
us-gaap Fair Value Of Assets Acquired
FairValueOfAssetsAcquired
734000000 usd
CY2024Q2 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
34000000 usd
CY2023Q2 us-gaap Liabilities Assumed1
LiabilitiesAssumed1
36000000 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
41000000 usd
us-gaap Liabilities Assumed1
LiabilitiesAssumed1
36000000 usd
CY2024Q2 dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
100000000 usd
CY2023Q2 dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
667000000 usd
dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
248000000 usd
dgx Fair Value Of Net Assets Acquired
FairValueOfNetAssetsAcquired
698000000 usd
CY2024Q2 dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
6000000 usd
CY2023Q2 dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
-88000000 usd
dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
0 usd
dgx Merger Consideration Paid Payable Net
MergerConsiderationPaidPayableNet
-88000000 usd
CY2024Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
106000000 usd
CY2023Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
579000000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
248000000 usd
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
610000000 usd
CY2024Q2 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
CY2023Q2 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1000000 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
1000000 usd
CY2024Q2 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
106000000 usd
CY2023Q2 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
578000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
248000000 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
609000000 usd
CY2024Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
52000000 usd
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
57000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
87000000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
101000000 usd
dgx Increase Decrease In Bank Overdrafts
IncreaseDecreaseInBankOverdrafts
-38000000 usd
dgx Increase Decrease In Bank Overdrafts
IncreaseDecreaseInBankOverdrafts
-26000000 usd
CY2024Q2 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
165000000 usd
CY2023Q4 us-gaap Malpractice Loss Contingency Accrual Undiscounted
MalpracticeLossContingencyAccrualUndiscounted
173000000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2397000000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2338000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4763000000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4669000000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
355000000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
348000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
655000000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
653000000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-41000000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-31000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-75000000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59000000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
314000000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
317000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
580000000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
594000000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74000000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
75000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
140000000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
140000000 usd
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
7000000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
8000000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
12000000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
240000000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
249000000 usd
us-gaap Profit Loss
ProfitLoss
448000000 usd
us-gaap Profit Loss
ProfitLoss
466000000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
11000000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
14000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
25000000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
29000000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
229000000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
235000000 usd
us-gaap Net Income Loss
NetIncomeLoss
423000000 usd
us-gaap Net Income Loss
NetIncomeLoss
437000000 usd
CY2024Q2 dgx Percentageof Net Revenues
PercentageofNetRevenues
1
CY2023Q2 dgx Percentageof Net Revenues
PercentageofNetRevenues
1
dgx Percentageof Net Revenues
PercentageofNetRevenues
1
dgx Percentageof Net Revenues
PercentageofNetRevenues
1
CY2024Q2 dgx Percentageof Net Accounts Receivable
PercentageofNetAccountsReceivable
1
CY2023Q4 dgx Percentageof Net Accounts Receivable
PercentageofNetAccountsReceivable
1
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001022079-24-000156-index-headers.html Edgar Link pending
0001022079-24-000156-index.html Edgar Link pending
0001022079-24-000156.txt Edgar Link pending
0001022079-24-000156-xbrl.zip Edgar Link pending
dgx-20240630.htm Edgar Link pending
dgx-20240630.xsd Edgar Link pending
dgx06302024ex101.htm Edgar Link pending
dgx06302024ex101001.jpg Edgar Link pending
dgx06302024ex101002.jpg Edgar Link pending
dgx06302024ex101003.jpg Edgar Link pending
dgx06302024ex101004.jpg Edgar Link pending
dgx06302024ex101005.jpg Edgar Link pending
dgx06302024ex101006.jpg Edgar Link pending
dgx06302024ex101007.jpg Edgar Link pending
dgx06302024ex101008.jpg Edgar Link pending
dgx06302024ex101009.jpg Edgar Link pending
dgx06302024ex101010.jpg Edgar Link pending
dgx06302024ex101011.jpg Edgar Link pending
dgx06302024ex101012.jpg Edgar Link pending
dgx06302024ex101013.jpg Edgar Link pending
dgx06302024ex101014.jpg Edgar Link pending
dgx06302024ex101015.jpg Edgar Link pending
dgx06302024ex101016.jpg Edgar Link pending
dgx06302024ex101017.jpg Edgar Link pending
dgx06302024ex101018.jpg Edgar Link pending
dgx06302024ex101019.jpg Edgar Link pending
dgx06302024ex101020.jpg Edgar Link pending
dgx06302024ex101021.jpg Edgar Link pending
dgx06302024ex101022.jpg Edgar Link pending
dgx06302024ex101023.jpg Edgar Link pending
dgx06302024ex101024.jpg Edgar Link pending
dgx06302024ex101025.jpg Edgar Link pending
dgx06302024ex101026.jpg Edgar Link pending
dgx06302024ex101027.jpg Edgar Link pending
dgx06302024ex101028.jpg Edgar Link pending
dgx06302024ex101029.jpg Edgar Link pending
dgx06302024ex101030.jpg Edgar Link pending
dgx06302024ex101031.jpg Edgar Link pending
dgx06302024ex101032.jpg Edgar Link pending
dgx06302024ex101033.jpg Edgar Link pending
dgx06302024ex101034.jpg Edgar Link pending
dgx06302024ex101035.jpg Edgar Link pending
dgx06302024ex101036.jpg Edgar Link pending
dgx06302024ex101037.jpg Edgar Link pending
dgx-20240630_pre.xml Edgar Link unprocessable
dgx-20240630_lab.xml Edgar Link unprocessable
dgx-20240630_htm.xml Edgar Link completed
dgx06302024ex101038.jpg Edgar Link pending
dgx06302024ex101039.jpg Edgar Link pending
dgx06302024ex101040.jpg Edgar Link pending
dgx06302024ex101041.jpg Edgar Link pending
dgx06302024ex101042.jpg Edgar Link pending
dgx06302024ex101043.jpg Edgar Link pending
dgx06302024ex101044.jpg Edgar Link pending
dgx06302024ex101045.jpg Edgar Link pending
dgx06302024ex101046.jpg Edgar Link pending
dgx06302024ex101047.jpg Edgar Link pending
dgx06302024ex101048.jpg Edgar Link pending
dgx06302024ex101049.jpg Edgar Link pending
dgx06302024ex101050.jpg Edgar Link pending
dgx06302024ex101051.jpg Edgar Link pending
dgx06302024ex101052.jpg Edgar Link pending
dgx06302024ex101053.jpg Edgar Link pending
dgx06302024ex101054.jpg Edgar Link pending
dgx06302024ex101055.jpg Edgar Link pending
dgx06302024ex101056.jpg Edgar Link pending
dgx06302024ex101057.jpg Edgar Link pending
dgx06302024ex101058.jpg Edgar Link pending
dgx06302024ex101059.jpg Edgar Link pending
dgx06302024ex101060.jpg Edgar Link pending
dgx06302024ex101061.jpg Edgar Link pending
dgx06302024ex101062.jpg Edgar Link pending
dgx06302024ex101063.jpg Edgar Link pending
dgx06302024ex101064.jpg Edgar Link pending
dgx06302024ex101065.jpg Edgar Link pending
dgx06302024ex101066.jpg Edgar Link pending
dgx06302024ex101067.jpg Edgar Link pending
dgx06302024ex101068.jpg Edgar Link pending
dgx06302024ex101069.jpg Edgar Link pending
dgx06302024ex101070.jpg Edgar Link pending
dgx06302024ex101071.jpg Edgar Link pending
dgx06302024ex101072.jpg Edgar Link pending
dgx06302024ex101073.jpg Edgar Link pending
dgx06302024ex101074.jpg Edgar Link pending
dgx06302024ex101075.jpg Edgar Link pending
dgx06302024ex101076.jpg Edgar Link pending
dgx06302024ex101077.jpg Edgar Link pending
dgx06302024ex101078.jpg Edgar Link pending
dgx06302024ex101079.jpg Edgar Link pending
dgx06302024ex101080.jpg Edgar Link pending
dgx06302024ex101081.jpg Edgar Link pending
dgx06302024ex101082.jpg Edgar Link pending
dgx06302024ex101083.jpg Edgar Link pending
dgx06302024ex101084.jpg Edgar Link pending
dgx06302024ex101085.jpg Edgar Link pending
dgx06302024ex101086.jpg Edgar Link pending
dgx06302024ex101087.jpg Edgar Link pending
dgx06302024ex101088.jpg Edgar Link pending
dgx06302024ex101089.jpg Edgar Link pending
dgx06302024ex101090.jpg Edgar Link pending
dgx06302024ex101091.jpg Edgar Link pending
dgx06302024ex101092.jpg Edgar Link pending
dgx06302024ex101093.jpg Edgar Link pending
dgx06302024ex101094.jpg Edgar Link pending
dgx06302024ex101095.jpg Edgar Link pending
dgx06302024ex101096.jpg Edgar Link pending
dgx06302024ex101097.jpg Edgar Link pending
dgx06302024ex101098.jpg Edgar Link pending
dgx06302024ex101099.jpg Edgar Link pending
dgx06302024ex22.htm Edgar Link pending
dgx06302024ex311.htm Edgar Link pending
dgx06302024ex312.htm Edgar Link pending
dgx06302024ex321.htm Edgar Link pending
dgx06302024ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
dgx-20240630_cal.xml Edgar Link unprocessable
dgx-20240630_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable